RATIONALE: Binding of maternal anti-Ro/La antibodies to cognate antigen expressed on apoptotic cardiocytes decreases clearance by healthy cardiocytes, which may contribute to the development of autoimmune associated congenital heart block and fatal cardiomyopathy. OBJECTIVE: Given recent evidence implicating the urokinase plasminogen activator receptor (uPAR) as a "don't eat me" signal during efferocytosis, experiments addressed whether surface bound anti-Ro antibodies inhibit apoptotic cell removal via an effect on the expression/function of the urokinase-type plasminogen activator protease uPA/uPAR system. METHODS AND RESULTS: As assessed by flow cytometry and confocal microscopy, uPAR colocalizes and interacts with Ro60 on the surface of apoptotic human fetal cardiocytes. Blocking of uPAR enhances phagocytosis of apoptotic cardiocytes by healthy cardiocytes and reverses the anti-Ro60-dependent impaired clearance of apoptotic cardiocytes. Binding of anti-Ro60 antibodies to apoptotic cardiocytes results in increased uPAR expression, as well as enhanced uPA activity. The binding of anti-Ro60 did not alter other surface molecules involved in cell recognition (calreticulin, CD31, or CD47). CONCLUSIONS: These data suggest that increased uPAR expression and uPA activity induced by anti-Ro60 binding to the apoptotic fetal cardiocyte provide a molecular basis by which these antibodies inhibit efferocytosis and ultimately lead to scar of the fetal conduction system and working myocardium.
RATIONALE: Binding of maternal anti-Ro/La antibodies to cognate antigen expressed on apoptotic cardiocytes decreases clearance by healthy cardiocytes, which may contribute to the development of autoimmune associated congenital heart block and fatal cardiomyopathy. OBJECTIVE: Given recent evidence implicating the urokinase plasminogen activator receptor (uPAR) as a "don't eat me" signal during efferocytosis, experiments addressed whether surface bound anti-Ro antibodies inhibit apoptotic cell removal via an effect on the expression/function of the urokinase-type plasminogen activator protease uPA/uPAR system. METHODS AND RESULTS: As assessed by flow cytometry and confocal microscopy, uPAR colocalizes and interacts with Ro60 on the surface of apoptotic human fetal cardiocytes. Blocking of uPAR enhances phagocytosis of apoptotic cardiocytes by healthy cardiocytes and reverses the anti-Ro60-dependent impaired clearance of apoptotic cardiocytes. Binding of anti-Ro60 antibodies to apoptotic cardiocytes results in increased uPAR expression, as well as enhanced uPA activity. The binding of anti-Ro60 did not alter other surface molecules involved in cell recognition (calreticulin, CD31, or CD47). CONCLUSIONS: These data suggest that increased uPAR expression and uPA activity induced by anti-Ro60 binding to the apoptotic fetal cardiocyte provide a molecular basis by which these antibodies inhibit efferocytosis and ultimately lead to scar of the fetal conduction system and working myocardium.
Authors: Robert M Clancy; Anca D Askanase; Raj P Kapur; Efstathia Chiopelas; Natalie Azar; M Eugenia Miranda-Carus; Jill P Buyon Journal: J Immunol Date: 2002-08-15 Impact factor: 5.422
Authors: M E Miranda; C E Tseng; W Rashbaum; R L Ochs; C A Casiano; F Di Donato; E K Chan; J P Buyon Journal: J Immunol Date: 1998-11-01 Impact factor: 5.422
Authors: Joanne H Reed; Robert M Clancy; Anthony W Purcell; Mimi Y Kim; Tom P Gordon; Jill P Buyon Journal: J Immunol Date: 2011-05-20 Impact factor: 5.422
Authors: Gang Liu; Yanping Yang; Shanzhong Yang; Sami Banerjee; Andressa De Freitas; Arnaud Friggeri; Kasey I Davis; Edward Abraham Journal: PLoS One Date: 2011-10-05 Impact factor: 3.240
Authors: Shuang Zhang; Xin-Yi Yeap; Matthew DeBerge; Nivedita K Naresh; Kevin Wang; Zhengxin Jiang; Jane E Wilcox; Steven M White; John P Morrow; Paul W Burridge; Daniel Procissi; Evan A Scott; William Frazier; Edward B Thorp Journal: JACC Basic Transl Sci Date: 2017-08
Authors: Matthew DeBerge; Shuang Zhang; Kristofor Glinton; Luba Grigoryeva; Islam Hussein; Esther Vorovich; Karen Ho; Xunrong Luo; Edward B Thorp Journal: Front Immunol Date: 2017-11-01 Impact factor: 7.561